Transform pharmaceutical authoring processes with Fonto Integrated Authoring Platform

Latest innovation, developed in collaboration with leading pharma companies, dramatically simplifies content creation, review, publishing and regulatory submissions

Chalfont Saint Peter, UK
3/13/2024 10:00:00 AM

RWS, a content solutions company, powered by technology and human expertise, announces the launch of the Fonto Integrated Authoring Platform (IAP), a game-changing solution designed to streamline the document creation and publishing process for the pharmaceutical industry.

Fonto transforms the complex and time-consuming task of drafting, editing and reviewing critical business documents – including regulatory submissions and drug applications – into a straightforward, efficient process. Its user-friendly interface, similar to Microsoft Word, allows experts to collaborate centrally, enhancing the speed and quality of document production.

“It would usually take me a minimum of 10 to 15 hours to format a significant document – whereas now it takes me about five hours to achieve the same result,” explains a medical writer from a large pharma company.

“We’re delighted to announce the availability of Fonto IAP,” explains Jan Benedictus, Managing Director, Fonto. “The technology is born out of a close collaboration between our pharma clients and the Fonto and Tridion teams, resulting in a breakthrough for regulated companies with heavy demands on content creation.”

Fonto IAP seamlessly integrates with external data sources, automating the creation of working documents. It also ensures consistency of content through templates and standardization, ensuring all documents are compliant with regulatory requirements.

“We release five new products to the market per year and that number is growing. Per new drug application, our scientists spend 800 days on automatable work, i.e. collecting, retyping, changing, inserting and formatting content and data. We needed to speed up these processes and reduce the amount of costly manual work. That’s why we’ve introduced Fonto IAP,” according to a Digital Transformation Program Lead at a large pharmaceutical company.

Click here for more information.

Notes to editor:

Fonto IAP has been designed to support a wide range of use-cases and document types, including the creation and management of clinical protocols and reports, informed consent forms, quality assurance documents, chemistry manufacturing and controls (CMC), electronic common technical documents (eCTD) sections 2 and 3, structured product labelling (SPL) and electronic product information (ePI).

Fonto IAP benefits organizations where their document types and their associated processes share one or multiple of the characteristics below:

  • Multiple variations of documents where large parts are shared or overlap with other documentation.
  • Highly templated documents and the presence of large quantities of data in the form of tables and/or charts.
  • Documents that require a high level of manual work to be authored, reviewed, checked and maintained.
  • Underlying processes that are expected to shift from document-centric to data-centric.
  • Fonto and Tridion are part of RWS’s structured authoring and content management portfolio of solutions.

About us

RWS is a content solutions company, powered by technology and human expertise. We grow the value of ideas, data and content by making sure organizations are understood. Everywhere.


Our proprietary technology, 45+ AI patents and human experts help organizations bring ideas to market faster, build deeper relationships across borders and cultures, and enter new markets with confidence – growing their business and connecting them to a world of opportunities.


It’s why over 80 of the world’s top 100 brands trust RWS to drive innovation, inform decisions and shape brand experiences.


With 60+ global locations, across five continents, our teams work with businesses across almost all industries. Innovating since 1958, RWS is headquartered in the UK and publicly listed on AIM, the London Stock Exchange regulated market (RWS.L).


For further information, please visit: rws.com.


© 2025 All rights reserved. Information contained herein is deemed confidential and the proprietary information of RWS Group*.
*RWS Group shall mean RWS Holdings plc for and on behalf of its affiliates and subsidiaries.